Click on headlines below to download research
Kinarus has reported that its preclinical data on lead candidate KIN001 have shown strong antiviral efficacy against SARS-CoV-2 Omicron subvariants BA.2…
Kinarus received a notice of allowability from the US Patent and Trademark Office (USPTO) for its patent application No. 16/500,504 (‘methods of…
Kinarus recently reported H122 financial results and reiterated its key objectives and guidance for lead candidate KIN001 in the three targeted indications,…